Beeline Medicines launches with $300M to develop precision therapies for autoimmune diseases, advancing lupus drug afimetoran.

Beeline Medicines, a clinical-stage biotech company, officially launched with $300 million in Series A funding led by Bain Capital to develop precision therapies for autoimmune and inflammatory diseases. Their lead drug candidate, afimetoran, is a once-daily oral therapy for lupus, currently completing Phase 2 trials with plans for pivotal development in late 2026. The company’s pipeline includes five programs licensed from Bristol Myers Squibb, targeting various immune-mediated diseases with innovative, mechanism-based treatments. Led by experienced executives, Beeline aims to transform care by addressing underlying disease biology and improving patient outcomes.